ESCRS - FPS09.05 - Real World Outcomes Of A Novel Wavefront Shaping Presbyopia-Correcting Iol In Netherlands Clinics

Real World Outcomes Of A Novel Wavefront Shaping Presbyopia-Correcting Iol In Netherlands Clinics

Published 2022 - 40th Congress of the ESCRS

Reference: FPS09.05 | Type: Free paper | DOI: 10.82333/q99v-y290

Authors: Rudy M.M.A. Nuijts* 1 , Joukje Wanten 1 , Noel J.C Bauer 1 , Caridad Perez-Vives 2 , Frank J.H.M van den Biggelaar 1

1University Eye Clinic Maastricht,Maastricht,Netherlands, 2Alcon Vision LLC,Fort Worth, TX,United States

Purpose

To report real world visual outcomes with the Acrysof IQ Vivity and Acrysof IQ Vivity Toric presbyopia correcting IOL models DFT015, DFT215, DFT315, DFT415, and DFT515 in Dutch clinics.

Setting

Multicenter, ambispective registry study conducted in Europe, the UK and Australia evaluating the performance of bilaterally implanted AcrySof IQ Vivity and AcrySof IQ Vivity Toric IOL in a real world setting through routine clinical practice.

Methods

This is a sub-analysis of subjects enrolled from Dutch sites to date. After a minimum of 3 months post-op follow up per local clinical practice standards, subjects implanted with the AcrySof IQ Vivity and Vivity Toric IOL in both eyes underwent visual performance assessments of visual acuity at distance, intermediate (66 cm) and near (40 cm) distances. Patient satisfaction and spectacle independence recorded via validated questionnaires and patient reports of visual disturbances are reported. 

Results

To date, 757 subjects are enrolled globally, with 76 (10.0%) subjects enrolled in Dutch sites. Mean UCDVA was 0.003 ± 0.114 logMAR (20/20 Snellen), mean UCIVA was 0.026 ± 0.098 logMAR (~ 20/25 Snellen) and mean UCNVA was 0.201 ± 0.122 logMAR (~20/32 Snellen). 94.4% of patients reported to be satisfied with their sight and 86.1% reported no difficulty reading subtitles on TV. The percentage of subjects reporting never/rarely needing to wear eyeglasses was  54.3% for near vision, 81.7% for intermediate vision and 91.6% for distance vision. Percentage of patients reporting no halos, glare and starburst was 93.1%, 94.4% and 100.0%, respectively.

Conclusions

This assessment of patients bilaterally implanted in the Netherlands with the AcrySof IQ Vivity and AcrySof IQ Vivity Toric IOL evaluated in regular clinical settings suggests very good visual outcomes, high levels of vision patient satisfaction with low needs to wearing spectacles for intermediate and distance activities and also experiencing mild to none visual disturbances.